NO170280C - Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater

Info

Publication number
NO170280C
NO170280C NO843836A NO843836A NO170280C NO 170280 C NO170280 C NO 170280C NO 843836 A NO843836 A NO 843836A NO 843836 A NO843836 A NO 843836A NO 170280 C NO170280 C NO 170280C
Authority
NO
Norway
Prior art keywords
sub
preparation
therapeutic active
analogy procedure
sulphamate derivatives
Prior art date
Application number
NO843836A
Other languages
English (en)
Norwegian (no)
Other versions
NO170280B (no
NO843836L (no
Inventor
Bruce Eliot Maryanoff
Joseph Francis Gardocki
Original Assignee
Mcneilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24134409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO170280(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneilab Inc filed Critical Mcneilab Inc
Publication of NO843836L publication Critical patent/NO843836L/no
Publication of NO170280B publication Critical patent/NO170280B/no
Publication of NO170280C publication Critical patent/NO170280C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO843836A 1983-09-26 1984-09-25 Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater NO170280C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,475 US4513006A (en) 1983-09-26 1983-09-26 Anticonvulsant sulfamate derivatives

Publications (3)

Publication Number Publication Date
NO843836L NO843836L (no) 1985-03-27
NO170280B NO170280B (no) 1992-06-22
NO170280C true NO170280C (no) 1992-09-30

Family

ID=24134409

Family Applications (2)

Application Number Title Priority Date Filing Date
NO843836A NO170280C (no) 1983-09-26 1984-09-25 Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
NO1997004C NO1997004I1 (no) 1983-09-26 1997-05-09 Topiramat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1997004C NO1997004I1 (no) 1983-09-26 1997-05-09 Topiramat

Country Status (18)

Country Link
US (1) US4513006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0138441B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS60109558A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR920001775B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE36149T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU564842B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1241951A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3473143D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK165004C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES536225A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI79095C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU194540B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE57684B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9202630A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL990025I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO170280C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ209494A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA847550B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
PT736029E (pt) * 1993-12-23 2006-05-31 Ortho Mcneil Pharm Inc Sulfamatos de pseudofructopiranose anticonvulsivos
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
KR970027051A (ko) * 1995-11-02 1997-06-24 조규향 카바모일기를 포함하는 신규한 설파메이트 화합물
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
UA43449C2 (uk) * 1996-06-28 2001-12-17 Орто-Макнейл Фармасьютікел, Інк. Спосіб лікування псоріазу
AU3501697A (en) * 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
SK284305B6 (sk) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
NZ334981A (en) * 1996-10-08 2000-08-25 Ortho Mcneil Pharm Inc Anti-convulsant derivatives such as topiramate for treating neuropathic pain
JP3744089B2 (ja) * 1996-12-02 2006-02-08 富士電機ホールディングス株式会社 マグネトロンスパッタ成膜装置および成膜方法
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
WO2000023059A2 (en) * 1998-10-20 2000-04-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating alcohol dependency
DK1143917T3 (da) * 1998-11-17 2004-06-01 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
TR200102711T2 (tr) * 1999-01-19 2001-12-21 Ortho-Mcneil Pharmaceutical, Inc. Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
AR022321A1 (es) * 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
TR200102205T2 (tr) * 1999-02-01 2002-01-21 Ortho-Mcneil Pharmaceutical, Inc. Anti-konvülsan türevlerinin bulimia nevruza tedavisinde kullanılmaları.
MXPA01008038A (es) * 1999-02-08 2002-04-24 Johnson 6 Johnson Derivados anticonvulsionantes utiles en el tratamiento de autismo.
KR100664612B1 (ko) * 1999-02-17 2007-01-04 오르토-맥네일 파마슈티칼, 인코퍼레이티드 본태성 진전의 치료에 유용한 항경련성 유도체
AU779248B2 (en) * 1999-02-24 2005-01-13 University Of Cincinnati, The Use of sulfamate derivatives for treating impulse control disorders
CA2369091C (en) * 1999-04-08 2005-01-11 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
WO2000061140A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514810A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering lipids
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
JP2002543123A (ja) * 1999-04-30 2002-12-17 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド コカイン依存症の処置において有用な抗痙攣性誘導体
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US6486198B1 (en) * 1999-05-28 2002-11-26 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
PL213323B1 (pl) * 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
US7335650B2 (en) * 2000-01-14 2008-02-26 Sterix Limited Composition
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MXPA03000136A (es) * 2000-07-07 2004-09-13 Johnson & Johnson Derivados anticonvulsivos utiles para prevenir el desarrollo de la diabetes mellitus de tipo ii o del sindromex.
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
JP2004505043A (ja) 2000-08-02 2004-02-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド うつ病の治療で用いるに有用な抗痙攣性誘導体
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002064210A2 (en) 2000-10-30 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
WO2002043731A2 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
EA200300432A1 (ru) 2000-11-30 2003-10-30 Пфайзер Продактс Инк. Комбинация гамк-агонистов и ингибиторов сорбитолдегидрогеназы
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
ES2284858T3 (es) * 2001-02-02 2007-11-16 Ortho-Mcneil Pharmaceutical, Inc. Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
MXPA04004380A (es) * 2001-11-06 2005-06-08 Johnson & Johnson Tratamiento y prevencion de parestesia que comprende co-terapia con derivados anticonvulsivos y potasio.
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
JP2005518439A (ja) * 2002-02-26 2005-06-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US7060725B2 (en) * 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
RU2341259C2 (ru) * 2002-05-17 2008-12-20 Дюк Юниверсити Способ лечения ожирения
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
MXPA05001184A (es) * 2002-07-29 2005-09-12 Johnson & Johnson Formulaciones y formas de dosificacion para administracion controlada de topiramato.
ATE358488T1 (de) * 2002-09-13 2007-04-15 Motac Neuroscience Ltd Behandlung von dyskinesie mit 2,3-benzodiazepinen
CN100502856C (zh) * 2002-09-17 2009-06-24 默塔克神经科学有限公司 运动障碍的治疗
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
RU2005122008A (ru) * 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
UA81657C2 (ru) * 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
WO2004089965A2 (en) * 2003-04-07 2004-10-21 Cipla Ltd Topiramate and processes for the preparation thereof
PT1617832E (pt) 2003-04-29 2008-06-19 Orexigen Therapeutics Inc Composições com efeito na perda de peso
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
BRPI0410271A (pt) 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
EP1653922A2 (en) * 2003-08-06 2006-05-10 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
US20070154550A1 (en) * 2003-08-28 2007-07-05 Potdar Arti Pharmaceutical composition comprising anticonvulsant with taste mask coating
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
CN1882533B (zh) 2003-09-19 2010-06-09 詹森药业有限公司 4-((苯氧基烷基)硫基)-苯氧基乙酸及其类似物
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005065646A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050203287A1 (en) * 2004-03-11 2005-09-15 Chandrasekhar Batchu Process for the preparation of sulfamate derivatives
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
ES2270243T3 (es) 2004-08-19 2007-04-01 Helm Ag Procedimiento para la preparacion de topiramato.
EA010977B1 (ru) * 2004-08-24 2008-12-30 Янссен Фармацевтика Н.В. Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
CN101257889A (zh) * 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ATE534387T1 (de) * 2005-09-23 2011-12-15 Janssen Pharmaceutica Nv Hexahydro-cycloheptapyrazol-cannabinoid- modulatoren
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
AU2006292051B2 (en) 2005-09-23 2012-11-15 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
WO2007044215A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
JP2009510085A (ja) * 2005-09-29 2009-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼインヒビターとしての大型複素環式化合物
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007106400A2 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TW200812574A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
WO2008010231A2 (en) * 2006-05-26 2008-01-24 Alembic Limited A process for the purification of topiramate
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
PT2061458E (pt) * 2006-09-15 2015-03-11 Univ Minnesota Composições de topiramato e métodos para a sua utilização
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR20160072276A (ko) * 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN101553204B (zh) * 2006-12-04 2013-10-30 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EA201071120A1 (ru) * 2008-03-26 2011-06-30 Янссен Фармацевтика Н.В. Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
EP2340246A2 (en) 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20120121692A1 (en) * 2009-05-08 2012-05-17 Shandong University Compounds and compositions comprising cdk inhibitors and methods for treating cancer
RU2616496C2 (ru) * 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
WO2011096934A1 (en) 2010-02-05 2011-08-11 Scinopharm Taiwan, Ltd. Process for the preparation and purification of topiramate
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
MX365914B (es) 2013-03-15 2019-06-20 Aprecia Pharmaceuticals LLC Forma de dosificación de topiramato dispersable rápidamente.
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103910770B (zh) * 2014-03-14 2017-01-04 天津南开允公医药科技有限公司 一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997585A (en) * 1974-12-30 1976-12-14 Ortho Pharmaceutical Corporation Aliphatic sulfamates

Also Published As

Publication number Publication date
ZA847550B (en) 1986-05-28
NL990025I1 (nl) 1999-11-01
NO170280B (no) 1992-06-22
FI843765L (fi) 1985-03-27
MX9202630A (es) 1992-06-30
FI843765A0 (fi) 1984-09-25
AU564842B2 (en) 1987-08-27
EP0138441A2 (en) 1985-04-24
DK198191A (da) 1991-12-09
DK165004B (da) 1992-09-28
ES8602634A1 (es) 1985-11-16
NO843836L (no) 1985-03-27
DK165003B (da) 1992-09-28
DK198291A (da) 1991-12-09
DK173923B1 (da) 2002-02-18
HU194540B (en) 1988-02-29
HUT36784A (en) 1985-10-28
FI79095C (fi) 1989-11-10
AU3350484A (en) 1985-04-04
DK198291D0 (da) 1991-12-09
IE842444L (en) 1985-03-26
DK457784A (da) 1985-03-27
KR920001775B1 (ko) 1992-03-02
EP0138441B1 (en) 1988-08-03
JPH05331132A (ja) 1993-12-14
IE57684B1 (en) 1993-02-24
CA1241951A (en) 1988-09-13
DK198191D0 (da) 1991-12-09
KR850002264A (ko) 1985-05-10
ATE36149T1 (de) 1988-08-15
NO1997004I1 (no) 1997-05-09
DK457784D0 (da) 1984-09-25
DE3473143D1 (de) 1988-09-08
ES536225A0 (es) 1985-11-16
NL990025I2 (nl) 1999-12-01
JPH055824B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-01-25
FI79095B (fi) 1989-07-31
DK165004C (da) 1993-02-08
US4513006A (en) 1985-04-23
EP0138441A3 (en) 1986-08-27
DK165003C (da) 1993-02-08
NZ209494A (en) 1987-03-06
JPS60109558A (ja) 1985-06-15

Similar Documents

Publication Publication Date Title
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
CA2152486A1 (en) Anticonvulsant sorbopyranose sulfamates
HUT34746A (en) Process for the production of 2-pyrimidinil-1-piperazine-derivatives and of medical preparations containing them as agent
ES8606282A1 (es) Un procedimiento de preparar derivados de acidos quinolin- ynaftiridin-carboxilicos
ES8801242A1 (es) Un procedimiento para la preparacion de metanosulfonatos de dioxolano.
ES539123A0 (es) Un compuesto de 3-indolcarboxamida
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
ZA839620B (en) Carbamate derivatives,process for their preparation and pharmaceutical compositions containing them
HUT41025A (en) Process for preparing octahydro-indolizine derivatives and pharmaceutical compositions containing such compounds as active ingredients
PT87310A (pt) Process for the preparation of thiadiazole guanidines
HUT38920A (en) Process for producing anticonvulsive tetrahydro-1,2,4-oxadiazine-5-thion derivatives
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE51227T1 (de) Chinatsalze der antimalarischen verbindung mefloquin.

Legal Events

Date Code Title Description
MK1K Patent expired